급성 반복 발작 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 의료의 확대, 간질 치료의 개선을 목적으로 한 정부의 대처에 기인하고 있습니다. 예측 기간에 있어서의 주요한 동향으로서는 발작 예측에 있어서의 AI의 채용, 디지털 헬스 솔루션의 통합, 혁신적 치료를 위한 임상시험의 확대, 간질의 유전자 치료의 개발, 신규 약제 제제의 창출 등을 들 수 있습니다.
신경 질환의 유병률 증가는 급성 반복 발작 시장 성장을 가속할 것으로 예측됩니다. 인구의 고령화에 의한 곳이 크고, 고령자는 뇌의 퇴행성 변화를 받기 쉽고, 알츠하이머병, 파킨슨병, 뇌졸중 등의 질환의 리스크가 높아집니다. 신경세포의 손상, 인지기능의 저하, 장기적인 합병증의 원인이 되기 때문에 조기 개입이 매우 중요합니다. 예를 들어, 알츠하이머 협회에 따르면 2023년까지 약 670만 명의 65세 이상 미국인이 알츠하이머 치매를 앓았으며, 2060년에는 그 수가 1,380만 명으로 증가할 것으로 예상하고 있습니다.
급성 반복 발작 시장의 주요 기업은 약물 흡수를 개선하고 신속한 발작 완화를 제공하며 환자의 편의성을 높이기 위해 벤조디아제핀 뺨 측 필름과 같은 혁신적인 약물 전달 기술을 개발하고 있습니다. 이 협측 필름은 벤조디아제핀계 약제를 포함한 얇은 용해 가능한 시트로, 뺨의 안쪽에 붙이는 것으로, 구강 점막으로부터 신속하게 흡수되어, 신속한 발작 완화를 가져옵니다. 약물을 혈류로 신속하게 방출하고 발작의 지속 시간과 빈도를 줄임으로써 급성 반복 발작을 관리하도록 설계되었습니다. 2024년 12월, Aquestive Therapeutics Inc.는 미국 제품 의약품국(FDA)에서 7년간 희귀의약품(ODE)으로 독점권을 취득했습니다. Libervant는 간헐성 발작군과 급성 반복 발작의 급성기 치료에 사용됩니다. 중추신경억제제로서 작용하여 감마아미노부티르산(GABA)의 작용을 증강시켜 발작활동을 억제합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 급성 반복 발작 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 급성 반복 발작 시장 : 성장률 분석
- 세계의 급성 반복 발작 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 급성 반복 발작 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 급성 반복 발작 전체 시장(TAM)
제6장 시장 세분화
- 세계의 급성 반복 발작 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 벤조디아제핀
- 항전간제
- 바비투르산염
- 기타 약제 유형
- 세계의 급성 반복 발작 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 비강
- 직장
- 경구
- 기타 투여 경로
- 세계의 급성 반복 발작 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 클리닉
- 재택 케어
- 세계의 급성 반복 발작 시장 : 벤조디아제핀 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 디아제팜
- 로라제팜
- 미다졸람
- 클로나제팜
- 알프라졸람
- 세계의 급성 반복 발작 시장 : 항전간제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 레베티라세탐
- 페니토인
- 발프로에이트
- 카바마제핀
- 라모트리진
- 세계의 급성 반복 발작 시장 : 바비투르산염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 페노바르비탈
- 프리미돈
- 세계의 급성 반복 발작 시장 : 기타 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 코르티코스테로이드
- 정맥 면역글로불린(IVIG)
- 카나비노이드
제7장 지역별/국가별 분석
- 세계의 급성 반복 발작 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 급성 반복 발작 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 급성 반복 발작 시장 : 경쟁 구도
- 급성 반복 발작 시장 : 기업 프로파일
- Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
- Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
- GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
- Takeda Pharmaceutical Company Limited : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Boehringer Ingelheim International GmbH
- Bausch Health US LLC.
- UCB SA
- Eisai Co. Ltd.
- Sun Pharmaceutical Industries Ltd.
- Hikma Pharmaceuticals PLC
- Zydus Lifesciences Limited
- Endo International plc
- Lupin Limited
- Amneal Pharmaceuticals LLC
- Esteive Therapeutics Inc.
- Neurelis Inc.
- Grupo Ferrer Internacional SA
- UpsherSmith Laboratories LLC
- Aculys Pharma Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 급성 반복 발작 시장(2029년) : 새로운 기회를 제공하는 국가
- 급성 반복 발작 시장(2029년) : 새로운 기회를 제공하는 부문
- 급성 반복 발작 시장(2029년) : 성장 전략
제36장 부록
KTH
Acute repetitive seizures refer to a condition in which a person experiences multiple seizures within a short period, typically occurring within a 24-hour timeframe. These seizures often happen in quick succession, without a return to normal consciousness or baseline neurological function between episodes. They may be triggered by factors such as brain injury, infections, metabolic disturbances, or underlying neurological disorders.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main drug types used for managing acute repetitive seizures include benzodiazepines, antiepileptic drugs, barbiturates, and other related medications. Benzodiazepines are fast-acting drugs that help calm excessive brain activity, stopping acute seizures and preventing status epilepticus. These medications are administered via various routes, including intranasal, rectal, oral, and others. They are commonly used in hospitals, clinics, and home care settings by various end users.
The acute repetitive seizures market research report is one of a series of new reports from The Business Research Company that provides acute repetitive seizures market statistics, including the acute repetitive seizures industry global market size, regional shares, competitors with the acute repetitive seizures market share, detailed acute repetitive seizures market segments, market trends, and opportunities, and any further data you may need to thrive in the acute repetitive seizures industry. This acute repetitive seizures market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The acute repetitive seizures market size has grown rapidly in recent years. It will grow from $3.13 billion in 2024 to $3.51 billion in 2025 at a compound annual growth rate (CAGR) of 12.0%. The growth observed during the historic period can be attributed to the rising prevalence of epilepsy, increasing awareness of seizure management, growth in the use of rescue medications, improvements in diagnostic capabilities, and the expansion of healthcare access.
The acute repetitive seizures market size is expected to see rapid growth in the next few years. It will grow to $5.44 billion in 2029 at a compound annual growth rate (CAGR) of 11.6%. The growth projected for the forecast period can be attributed to the growing demand for non-invasive treatments, increasing investment in epilepsy research, the rising adoption of wearable seizure monitors, the expansion of telemedicine in neurology, and government initiatives aimed at improving epilepsy care. Key trends in the forecast period include the adoption of AI in seizure prediction, integration of digital health solutions, expanding clinical trials for innovative treatments, the development of gene therapies for epilepsy, and the creation of novel drug formulations.
The increasing prevalence of neurological disorders is expected to drive the growth of the acute repetitive seizures market. Neurological disorders affect the brain, nerves, or spinal cord, leading to issues with movement, speech, cognition, or other body functions. The rise in these conditions is largely due to an aging population, as older adults are more susceptible to degenerative brain changes, heightening the risk of diseases such as Alzheimer's, Parkinson's, and stroke. Acute repetitive seizures are a significant concern in the progression of neurological disorders, as they contribute to neuronal damage, cognitive decline, and long-term complications, making early intervention crucial. For example, according to the Alzheimer's Association, by 2023, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's dementia, with projections estimating that number will increase to 13.8 million by 2060. Therefore, the rising prevalence of neurological disorders is a key factor driving the growth of the acute repetitive seizures market.
Key players in the acute repetitive seizures market are developing innovative drug delivery technologies, such as the benzodiazepine buccal film, to improve drug absorption, provide rapid seizure relief, and enhance patient convenience. This buccal film, a thin dissolvable sheet containing benzodiazepine medication, is placed inside the cheek, where it quickly absorbs through the oral mucosa to deliver rapid relief. It is designed to manage acute repetitive seizures by swiftly releasing the medication into the bloodstream, reducing seizure duration and frequency. In December 2024, Aquestive Therapeutics Inc. received seven years of orphan drug exclusivity (ODE) from the U.S. Food and Drug Administration (FDA) for its product Libervant (diazepam) buccal film. Libervant is used for the acute treatment of intermittent seizure clusters and acute repetitive seizures. It acts as a central nervous system depressant, enhancing the effects of gamma-aminobutyric acid (GABA) to reduce seizure activity.
In January 2022, Aculys Pharma, Inc., a Japanese biopharmaceutical company specializing in neurological treatments, entered into a partnership with Neurelis, Inc. This collaboration aims to expand access to innovative therapies for neurological conditions, particularly seizure management. The companies secured licensing rights for advanced therapies, such as VALTOCO, a nasal spray used to manage seizure clusters and acute repetitive seizures. Neurelis, Inc., based in the U.S., focuses on neurology and psychiatry treatments, further enhancing their ability to deliver targeted therapies for patients suffering from these debilitating conditions.
Major players in the acute repetitive seizures market are Pfizer Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Bausch Health US LLC., UCB S.A., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Zydus Lifesciences Limited, Endo International plc, Lupin Limited, Amneal Pharmaceuticals LLC, Aquestive Therapeutics Inc., Neurelis Inc., Grupo Ferrer Internacional S.A., UpsherSmith Laboratories LLC, Aculys Pharma Inc.
North America was the largest region in the acute repetitive seizures market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute repetitive seizures report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Acute Repetitive Seizures market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acute repetitive seizures market consists of revenues earned by entities by providing services such as emergency medical services, hospital-based treatment, telemedicine and remote monitoring, specialty pharmacy services, seizure action plan development. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute repetitive seizures market also includes sales of intranasal rescue medications, rectal diazepam gel, anticonvulsants, and wearable seizure detection devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute Repetitive Seizures Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute repetitive seizures market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acute repetitive seizures ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute repetitive seizures market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Type: Benzodiazepines; Antiepileptic Drugs; Barbiturates; Other Drug Types
- 2) By Route Of Administration: Intranasal; Rectal; Oral; Other Routes Of Administrations
- 3) By End User: Hospitals; Clinics; Home Care Settings
- Subsegments:
- 1) By Benzodiazepines: Diazepam; Lorazepam; Midazolam; Clonazepam; Alprazolam
- 2) By Antiepileptic Drugs: Levetiracetam; Phenytoin; Valproate; Carbamazepine; Lamotrigine
- 3) By Barbiturates: Phenobarbital; Primidone
- 4) By Other Drug Types: Corticosteroids; Intravenous Immunoglobulins (IVIG); Cannabinoids
- Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Novartis AG; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Acute Repetitive Seizures Market Characteristics
3. Acute Repetitive Seizures Market Trends And Strategies
4. Acute Repetitive Seizures Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Acute Repetitive Seizures Growth Analysis And Strategic Analysis Framework
- 5.1. Global Acute Repetitive Seizures PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Acute Repetitive Seizures Market Growth Rate Analysis
- 5.4. Global Acute Repetitive Seizures Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Acute Repetitive Seizures Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Acute Repetitive Seizures Total Addressable Market (TAM)
6. Acute Repetitive Seizures Market Segmentation
- 6.1. Global Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Benzodiazepines
- Antiepileptic Drugs
- Barbiturates
- Other Drug Types
- 6.2. Global Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intranasal
- Rectal
- Oral
- Other Routes Of Administrations
- 6.3. Global Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Clinics
- Home Care Settings
- 6.4. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Benzodiazepines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Diazepam
- Lorazepam
- Midazolam
- Clonazepam
- Alprazolam
- 6.5. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Antiepileptic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Levetiracetam
- Phenytoin
- Valproate
- Carbamazepine
- Lamotrigine
- 6.6. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Barbiturates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Phenobarbital
- Primidone
- 6.7. Global Acute Repetitive Seizures Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Corticosteroids
- Intravenous Immunoglobulins (IVIG)
- Cannabinoids
7. Acute Repetitive Seizures Market Regional And Country Analysis
- 7.1. Global Acute Repetitive Seizures Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Acute Repetitive Seizures Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Acute Repetitive Seizures Market
- 8.1. Asia-Pacific Acute Repetitive Seizures Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Acute Repetitive Seizures Market
- 9.1. China Acute Repetitive Seizures Market Overview
- 9.2. China Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Acute Repetitive Seizures Market
- 10.1. India Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Acute Repetitive Seizures Market
- 11.1. Japan Acute Repetitive Seizures Market Overview
- 11.2. Japan Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Acute Repetitive Seizures Market
- 12.1. Australia Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Acute Repetitive Seizures Market
- 13.1. Indonesia Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Acute Repetitive Seizures Market
- 14.1. South Korea Acute Repetitive Seizures Market Overview
- 14.2. South Korea Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Acute Repetitive Seizures Market
- 15.1. Western Europe Acute Repetitive Seizures Market Overview
- 15.2. Western Europe Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Acute Repetitive Seizures Market
- 16.1. UK Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Acute Repetitive Seizures Market
- 17.1. Germany Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Acute Repetitive Seizures Market
- 18.1. France Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Acute Repetitive Seizures Market
- 19.1. Italy Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Acute Repetitive Seizures Market
- 20.1. Spain Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Acute Repetitive Seizures Market
- 21.1. Eastern Europe Acute Repetitive Seizures Market Overview
- 21.2. Eastern Europe Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Acute Repetitive Seizures Market
- 22.1. Russia Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Acute Repetitive Seizures Market
- 23.1. North America Acute Repetitive Seizures Market Overview
- 23.2. North America Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Acute Repetitive Seizures Market
- 24.1. USA Acute Repetitive Seizures Market Overview
- 24.2. USA Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Acute Repetitive Seizures Market
- 25.1. Canada Acute Repetitive Seizures Market Overview
- 25.2. Canada Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Acute Repetitive Seizures Market
- 26.1. South America Acute Repetitive Seizures Market Overview
- 26.2. South America Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Acute Repetitive Seizures Market
- 27.1. Brazil Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Acute Repetitive Seizures Market
- 28.1. Middle East Acute Repetitive Seizures Market Overview
- 28.2. Middle East Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Acute Repetitive Seizures Market
- 29.1. Africa Acute Repetitive Seizures Market Overview
- 29.2. Africa Acute Repetitive Seizures Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Acute Repetitive Seizures Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Acute Repetitive Seizures Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Acute Repetitive Seizures Market Competitive Landscape And Company Profiles
- 30.1. Acute Repetitive Seizures Market Competitive Landscape
- 30.2. Acute Repetitive Seizures Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis
31. Acute Repetitive Seizures Market Other Major And Innovative Companies
- 31.1. Boehringer Ingelheim International GmbH
- 31.2. Bausch Health US LLC.
- 31.3. UCB S.A.
- 31.4. Eisai Co. Ltd.
- 31.5. Sun Pharmaceutical Industries Ltd.
- 31.6. Hikma Pharmaceuticals PLC
- 31.7. Zydus Lifesciences Limited
- 31.8. Endo International plc
- 31.9. Lupin Limited
- 31.10. Amneal Pharmaceuticals LLC
- 31.11. Aquestive Therapeutics Inc.
- 31.12. Neurelis Inc.
- 31.13. Grupo Ferrer Internacional S.A.
- 31.14. UpsherSmith Laboratories LLC
- 31.15. Aculys Pharma Inc.
32. Global Acute Repetitive Seizures Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Acute Repetitive Seizures Market
34. Recent Developments In The Acute Repetitive Seizures Market
35. Acute Repetitive Seizures Market High Potential Countries, Segments and Strategies
- 35.1 Acute Repetitive Seizures Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Acute Repetitive Seizures Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Acute Repetitive Seizures Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
- 250617_r34744_Acute_Repetitive_Seizures_GMR_2025
